StockIQpro
NASDAQ:TWST

Twist Bioscience Corp

Track all markets on TradingView
Track all markets on TradingView

Twist Bioscience Corp's revenue grew 20.3% in fiscal 2025 to $376.6M while operating margin rose to −36.2%, its highest in 9 years. Free cash flow was −$75.6M, −20.1% of revenue, and the diluted share count rose 3.1%.Summary generated from Twist Bioscience Corp's SEC filings. Latest annual report filed Nov 17, 2025.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$376.6M
Revenue growth+20.3%
Revenue, 5-yr CAGR+33.1%
Gross margin50.7%
Operating margin−36.2%
Net margin−20.6%
ROICn/a
Return on equity−16.4%
Debt / equityn/a
Free cash flow−$75.6M
FCF margin−20.1%
Share count change+3.1%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue132204245313377
Operating income−153−235−217−221−136
Net income−152−218−205−209−78
Free cash flow−139−226−170−69−76

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)